公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 3 | 3 | |
2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 39 | 39 | |
2013 | The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme | Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F. | Oncology | 11 | 9 | |
2010 | Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors | CHIA-CHI LIN ; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; CHIH-HSIN YANG ; Mok T. | Journal of Thoracic Oncology | 26 | 22 | |
2019 | Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations | YEN-TING LIN ; JIN-SHING CHEN ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-LIN HSU ; Yang C.-Y.; KUAN-YU CHEN ; JIH-HSIANG LEE ; ZHONG-ZHE LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | International Journal of Cancer | 53 | 46 | |
2020 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer | WEN-CHI YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; CHONG-JEN YU ; ZHONG-ZHE LIN ; Lu S.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; SUNG-HSIN KUO | Clinical and Translational Radiation Oncology | 11 | 8 | |
2002 | Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma | Huang C.-L.; ZHONG-ZHE LIN ; Su I.-J.; Chao T.-Y.; HWEI-FANG TIEN ; Chang M.-C.; Huang M.-C.; Kao W.-Y.; JIH-LUH TANG ; KUN-HUEI YEH ; Wang C.-H.; CHIH-HUNG HSU ; Liu M.-Y.; ANN-LII CHENG | Leukemia and Lymphoma | 9 | 5 | |
2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
2013 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer | YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; CHIH-HSIN YANG ; Lai M.-S. | European Journal of Cancer | 20 | 18 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
2019 | Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status | Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN ; MING-CHIN YANG | PLoS ONE | 2 | 3 | |
2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 32 | 32 | |
2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 58 | 58 | |
2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
2022 | Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN ; Youkstetter J.; Hazra S.; Sen S.; ANN-LII CHENG ; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K. | British Journal of Cancer | 17 | 14 | |
2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 114 | 112 | |
2007 | Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma | YEN-SHEN LU ; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN ; Chen T.-J.; ANN-LII CHENG ; Chen C.-S. | Hepatology | 83 | 83 | |
2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 |